Gold prices rise from 2-wk low with focus on Russia-Ukraine, Jackson Hole
In a recent transaction, Guerrero Ramiro, a director at MAIA Biotechnology, Inc. (NYSE:MAIA), acquired common stock valued at approximately $49,999. The purchase involved 33,333 shares at a price of $1.50 per share, as reported in a Securities and Exchange Commission (SEC) Form 4 filing. The purchase comes as the stock has declined over 47% in the past six months, according to InvestingPro data, though the company maintains a healthy current ratio of 2.56.
Additionally, Ramiro acquired 33,333 warrants with an exercise price of $1.85 per share. These warrants, purchased under a Securities Purchase Agreement, are deemed options under the company’s 2021 Equity Incentive Plan. They become exercisable one year from the issuance date and expire six years later.
As a result of these transactions, Ramiro’s direct ownership in the company now stands at 568,218 shares of common stock.
In other recent news, MAIA Biotechnology has expanded its Phase 2 THIO-101 trial to include more patients with advanced non-small cell lung cancer (NSCLC), focusing on those unresponsive to prior treatments. The trial now features two arms, one evaluating THIO with Libtayo® and the other as a standalone treatment. Updated data from the trial indicates a median overall survival of 16.9 months, a significant improvement over standard chemotherapy outcomes. Additionally, MAIA Biotechnology secured $2.7 million through a private placement to fund Part C of the THIO-101 trial and for other operational needs. The company has also entered into a collaboration with BeiGene (NASDAQ:ONC) to explore THIO’s efficacy in combination with tislelizumab for various cancers, including hepatocellular carcinoma and colorectal cancer. In another development, MAIA announced revised employment agreements for key executives, including salary increases and updated terms. These adjustments align executive incentives with the company’s strategic goals. These developments reflect MAIA’s ongoing efforts to advance its clinical trials and expand its research collaborations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.